Steve Bloom is the Head of Division for Diabetes, Endocrinology and Metabolism, Chair of the academic Section of Endocrinology and Investigative Medicine at Imperial College London and Lead Clinician for Clinical Chemistry at Imperial College Healthcare NHS Trust. He heads a 40 strong research team investigating the physiology of regulatory peptides in CNS and periphery.
Professor Bloom received his undergraduate medical training at Cambridge University. His house officer, senior house officer and registrar posts were largely undertaken at The Middlesex Hospital, University College London, where he also received his MRC Clinical Research Fellowship training. He moved to the Royal Postgraduate Medical School at Hammersmith Hospital in 1974 where his roles have included Senior Lecturer (Consultant Physician), Reader in Medicine then Professor of Medicine and Chairman of the Academic Board. In Hammersmith Hospital he was Director of the Endocrinology Clinical Service and Deputy Director, Department of Medicine, Director of Chemical Pathology (renamed Metabolic Medicine) and later in the Hammersmith Hospitals Trust, Chief of Service for Pathology and Chief of Service Endocrinology and Diabetes.
In the 1980s Steve Bloom pioneered the discovery of several gut hormones and established their endocrine physiology, including their influence on appetite regulation and their simultaneous role as neurotransmitters. His research work over the years falls into five related categories: endocrinology clinical research, physiology and pathology of gut hormones, control of insulin release and insulin resistance, role of neuropeptides in organ control and the role of neuropeptides in CNS regulation of appetite and related hypothalamic functions. He currently leads a research group investigating hypothalamic appetite control systems and gut hormones. He has published over 1000 papers (excluding review articles) in journals such as Nature, J Biol Chem, PNAS, JCI and NEJM. His h-index is 157, the 64th highest cited academic in the world of all time.
This group’s discovery that oxyntomodulin reduces appetite offers a potential new treatment for obesity and in 2005 Steve co-founded spin out company ‘Thiakis Ltd’ to commercialise these findings. Thiakis was sold to Wyeth in 2008 for a reported £100 million (milestoned).
He chaired the Warwick Medical School Faculty Advisory Board. Steve has been a member of the Main Scientific Board for AstraZeneca and advisory boards for Upjohn and Novartis. He was Senior Censor then Vice President of the Royal College of Physicians, Chairman of the Medical Research Society, Chairman of the Society for Endocrinology, Chairman of BioScientifica and Chairman of the Diabetes UK Research Committee as well as a current and past member of a number of MRC grant committees. He was a Board member of the National Institute of Biological Standards and Control (NIBSC) and Chairman of the Scientific Committee. He was a member of the Rector's weekly executive committee in Imperial College London and a member of the West London NHS Area Health Authority. In 2013 he was elected a Fellow of the Royal Society.
et al., L-Arginine increases post-prandial circulating GLP-1 and PYY levels in humans, Obesity, ISSN:1930-7381
et al., Modulations of Human Resting Brain Connectivity by Kisspeptin 1 Enhance Sexual and Emotional Functions, Jci Insight, ISSN:2379-3708
Hope DCD, Tan TMM, Bloom SR, 2018, No guts, no loss: Toward the ideal treatment for obesity in the twenty-first century, Frontiers in Endocrinology, Vol:9
et al., 2018, Oxyntomodulin analogue increases energy expenditure via the glucagon receptor, Peptides, Vol:104, ISSN:0196-9781, Pages:70-77
, 2 patents applied for